Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2010-11-29 Regulatory Filings
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2010
Regulatory Filings Classification · 95% confidence The document is a correspondence letter dated November 29, 2010, from legal counsel responding to comments from the SEC Division of Corporation Finance regarding a Schedule TO-T filing related to a tender offer by Johnson & Johnson for Crucell N.V. The letter discusses regulatory definitions, control issues, and compliance with Rule 13e-3 under the Exchange Act. It references the Schedule TO filing and the tender offer transaction but does not itself contain financial statements or detailed financial results. The document is a regulatory correspondence related to a tender offer filing, not the tender offer document itself or a financial report. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2010-11-29 English
PRIMARY DOCUMENT
Director's Dealing
2010-11-29 English
PRIMARY DOCUMENT
Director's Dealing
2010-11-19 English
PRIMARY DOCUMENT
Director's Dealing
2010-11-16 English
SC TO-T Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It relates to a third-party tender offer by JJC Acquisition Company B.V., a subsidiary of Johnson & Johnson, to purchase all outstanding shares of Crucell N.V. The document includes detailed information about the tender offer, terms of the transaction, identity of the offeror, and exhibits such as the Offer Document and related agreements. This type of filing is specifically related to merger and acquisition activity, particularly tender offers. It is not an annual report, earnings release, or other financial report, but a regulatory filing concerning a takeover bid. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length and content confirm it is the actual filing, not just an announcement or summary.
2010-11-12 English
FORM 10-Q
Interim / Quarterly Report 9M 2010
2010-11-10 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.